# Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

> **NCT06196671** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** H101
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT06196671
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196671, "Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06196671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*